New method for long-term monitoring of intragastric pH

Shouko Ono, Mototsugu Kato, Yuji Ono, Masahiro Asaka

Shouko Ono, Mototsugu Kato, Division of Endoscopy, Hokkaido University Hospital, Sapporo 060-8648, Japan
Yuji Ono, Masahiro Asaka, Department of Gastroenterology, Hokkaido University Graduate School of Medicine, Sapporo 060-8648, Japan
Correspondence to: Mototsugu Kato, Division of Endoscopy, Hokkaido University Hospital Nishi-5, Kita-ku, Sapporo 060-8648, Japan
Telephone: +81-11-7161161 Fax: +81-11-7067867
Received: June 20, 2007 Revised: September 13, 2007

Abstract

AIM: Consecutive monitoring of intragastric pH using the Bravo® capsule.

METHODS: We put threads through a Bravo® capsule and then affixed it to the gastric wall by endoscopic hemoclipping in seven subjects. Study data were uploaded to a computer via Datalink every 48 h. In this way, repeated monitoring of intragastric pH was undertaken.

RESULTS: All subjects were able to monitor gastric pH over a 1-wk period, and five for > 2 wk. No complications were encountered during the monitoring. After pH monitoring, we safely retrieved the capsule endoscopically.

CONCLUSION: Clipping a Bravo® capsule onto the gastric wall enabled long-term intragastric pH monitoring. This is a methodological report of pH monitoring over a period of > 2 wk.

© 2007 WJG. All rights reserved.

Key words: Gastric pH; Ambulatory monitoring; Bravo system

INTRODUCTION

The Bravo® pH monitoring system is a catheter-less system. It has been reported to be useful clinically because it enables monitoring without pain while the subject undertakes daily activities[1-3]. The Bravo® capsule is attached to the esophageal mucosa by suction via the delivery system, and it is usually eliminated spontaneously within 1 wk[3]. According to manufacturer Medtronic, the average life of a capsule’s battery is 14 d, and consecutive pH monitoring is theoretically possible until the capsule battery goes flat. We used these characteristics of the Bravo® capsule to develop a new method for long-term monitoring of intragastric pH[6].

MATERIALS AND METHODS

Subjects and materials

The subjects of this study were seven Helicobacter pylori-negative volunteers. The Bravo® pH monitoring system (Medtronic, Shoreview, MI, USA), nylon threads, flexible overtube® (Sumitomo Bakelite, Tokyo, Japan), and stainless steel hemoclips (HX-200L-135; Olympus Optical, Tokyo, Japan) were prepared.

Preparation for Bravo® capsule

First, we removed the Bravo® capsule from its delivery system and we tied two nylon threads to the capsule and made each thread into a 2-cm diameter ring. Next, we confirmed a connection between the capsule and the receiver. The capsule was then calibrated in buffer solutions.

Placement of the Bravo® capsule

Endoscopic examinations with sedation were conducted on the subjects and results revealed the absence of any abnormal lesions. The flexible overtube® (Sumitomo Bakelite, Tokyo, Japan) was back-loaded onto the endoscope prior to the procedure. We carefully inserted the flexible overtube® with the tip of the endoscope inside the stomach. The Bravo® capsule was then passed through the tube into the stomach. Using hemoclips, the threads attached to the capsule were fixed on the greater curvature of the upper corpus (Figure 1).

Schedule

We administered antacids to determine whether the Bravo® capsule precisely monitored changes in intragastric pH. The subject was administered 150 mg ranitidine hydrochloride orally twice daily at 8:00 and 20:00 h. No limitation of meals and activities was imposed but meal times were set at 7:00, 12:00 and 19:00 h. Alcohol and tobacco were prohibited.

Analysis of pH data

Study data were uploaded to a computer via Datalink
Placement of the Bravo™ capsules took less than 5 min. No complications or side effects were observed during pH monitoring. All subjects were able to perform normal daily activities. Two of the seven subjects ended gastric pH monitoring because their capsule batteries went flat (at d 7 and 13). The other five succeeded in pH monitoring for 16 consecutive days. During this study, the average rate of captured data per day was 97.7%. A selection of the pH monitoring data is shown in Figure 2.

Gastric acid secretion was suppressed, beginning on the first day of ranitidine intake. However, during the medication period, the percentage time with pH < 4 increased and the median pH decreased. At the time of re-administration, the effect of the drug developed more slowly than at the first time it was given.

Retrieval of the Bravo™ capsules took less than 5 min. No capsule suffered any damage.

DISCUSSION

Using the standard vacuum method, it is more difficult to attach the Bravo™ capsule to a large lumen such as the stomach, than to the esophagus. It took us 15 min to place the capsule using the conventional method. The capsule was then eliminated on the fifth day. In previous studies of the Bravo™ system, intragastric pH monitoring was carried out for just 48 h[7-9]. Since an endoscopic procedure and administration of premedication can influence gastric acid secretion[10], a longer period for pH monitoring would be helpful for diagnosis[11-13]. In our study, we were able to monitor gastric pH for at least 1 wk.

We had some difficulty in passing threads through the capsule beforehand, but we needed only about 5 min to affix the capsule under endoscopic guidance[7]. The Bravo™ system has been reported to be safe[14,15], although there is a report of esophageal perforation during attachment of the capsule[16]. We used a flexible overtube® so that the capsule could pass safely through the cervical esophagus, a physiologic stricture. However, complications with the flexible overtube® have been reported[7], and so care must be taken when inserting it.

In addition, the precision of long-term pH monitoring using an antimony electrode fixed in stomach may create problems. However, in our study, pH rhythm was reflected by the effects of meals and medication, but the precision itself was not influenced. Some studies have suggested that the effects of histamine H2-receptor antagonists are attenuated during continuous treatment; an effect expressed as tolerance or tachyphylaxis[17,18]. Tachyphylaxis of ranitidine was observed in our study. The rates of captured data per day in the esophagus and stomach have been reported as 97.7% to 99.3%[7,14] and 98.3%[7], respectively. In our study, the rate was high and did not decrease over the 16-d period.

After monitoring for 16 d, we endoscopically retrieved the fixed capsules from the stomach. The Bravo™ capsule attached to the esophagus by suction was eliminated spontaneously through the gastrointestinal tract. However, we confirmed that a capsule fixed to the stomach for a long period did not suffer any damage.

H2-receptor antagonists and proton-pump inhibitors rapidly and potently suppress gastric acid secretion and are widely used for treatment of acid-related diseases[22-27]. However, they have some clinical weaknesses, tachyphylaxis and nocturnal gastric acid breakthrough[28-30], which have not been resolved. One reason has been the availability of only intermittent pH monitoring, but not long-term continuous monitoring. Our method is useful clinically not only for the diagnosis of acid-related diseases, but also for the elucidation of their problems.
In conclusion, we present a newly developed method for easy and simple long-term monitoring of intragastric pH using the Bravo® pH monitoring system.

ACKNOWLEDGMENTS

We thank Mrs. E Shouji (Department of Gastroenterology and Hematology, Hokkaido University Graduate School of Medicine) and Mr. T Iwasaki (Medical Care Support Division, Hokkaido University Hospital) for endoscopic support.

REFERENCES

1 Remes-Troche JM, Ibarra-Palomino J, Carmona-Sánchez RL, Valdivinos MA. Performance, tolerability, and symptoms related to prolonged pH monitoring using the Bravo system in Mexico. Am J Gastroenterol 2005; 100: 2382-2386
2 Pandolfini JE, Richter JE, Ours T, Guardino JM, Chapman J, Kahrilas PJ. Ambulatory esophageal pH monitoring using a wireless system. Am J Gastroenterol 2003; 98: 740-749
3 Gillies RS, Stratford JM, Booth MI, Dehn TC. Oesophageal pH monitoring using the Bravo catheter-free radio capsule. Eur J Gastroenterol Hepatol 2007; 19: 57-63
4 Pandolfini JE, Schreiner MA, Lee TJ, Zhang Q, Boniquit C, Kahrilas PJ. Comparison of the Bravo wireless and Digitrapper catheter-based pH monitoring systems for measuring mucosal acid exposure. Am J Gastroenterol 2005; 100: 1466-1476
5 Fox M. Bravo wireless versus catheter pH monitoring systems. Gut 2006; 55: 434-435
6 Ono S, Kato M, Ono Y, Nakagawa M, Shimizu Y, Takeda H, Asaka M. A new procedure for 16 consecutive days monitoring of intragastric pH. J Clin Gastroenterol 2008; 42:960
7 Yamaguchi T, Seza A, Odaka T, Shishido T, Ai M, Gen S, Kouzu T, Saisho H. Placement of the Bravo wireless pH monitoring capsule onto the gastric wall under endoscopic guidance. Gastrointest Endosc 2006; 63: 1046-1050
8 Pandolfini JE, Schreiner MA, Lee TJ, Zhang Q, Kahrilas PJ. Bravo capsule placement in the gastric cardia: a novel method for analysis of proximal stomach acid environment. Am J Gastroenterol 2005; 100: 1721-1727
9 Mori M, Suzuki H, Masaoka T, Imaeda H, Nomoto Y, Hosoda H, Nishizawa T, Kangawa K, Hibi T. Intravenous ghrelin administration enhances gastric acid secretion - evaluation using wireless pH capsule. Aliment Pharmacol Ther 2006; 24 Suppl 4:96-103
10 Ward EM, Devault KR, Bouras EP, Stark ME, Wolfsen HC, Davis DM, Nedrow SI, Achem SR. Successful oesophageal pH monitoring with a catheter-free system. Aliment Pharmacol Ther 2004; 19: 449-454
11 Bhat YM, McGrath KM, Bielefeldt K. Wireless esophageal pH monitoring: new technique means new questions. J Clin Gastroenterol 2006; 40: 116-121
12 Ahlawat SK, Novak DJ, Williams DC, Maher KA, Barton F, Benjamin SB. Day-to-day variability in acid reflux patterns using the BRAVO pH monitoring system. J Clin Gastroenterol 2006; 40: 20-24
13 Tseng D, Rizvi AZ, Fennerty MB, Jobe BA, Diggs BS, Sheppard BC, Gross SC, Swanstrom LL, White NB, Aye RW, Hunter JG. Forty-eight-hour pH monitoring increases sensitivity in detecting abnormal esophageal acid exposure. J Gastrointest Surg 2005; 9: 1043-1051; discussion 1051-1052
14 Wenner J, Johnsson F, Johannsson J, Oberg S. Wireless oesophageal pH monitoring: feasibility, safety and normal values in healthy subjects. Sand J Gastroenterol 2005; 40: 766-774
15 Marchese M, Spada C, Iacopini F, Familiari P, Shah SG, Tringali A, Costamagna G. Nonendoscopic transnasal placement of a wireless capsule for esophageal pH monitoring: feasibility, safety, and efficacy of a manometry-guided procedure. Endoscopy 2006; 38: 813-818
16 Fajardo NR, Wise JL, Locke GR, Murray JA, Talley NJ. Esophageal perforation after placement of Bravo wireless pH probe. Gastrointest Endosc 2006; 63: 184-185
17 Holderman WH, Ettzkorn KP, Patel SA, Harig JM, Watkins JL. Endoscopic findings and overtube-related complications associated with esophageal variceal ligation. J Clin Gastroenterol 1995; 21: 91-94
18 Wilder-Smith C, Lucifer T, Gennoni M, Zeyen B, Varga L, Roehmuel J, Merki HS. Loss of acid suppression during dosing with H2-receptor antagonists. Aliment Pharmacol Ther 1999; 4 Suppl 1: 15-27
19 Nwokolo CU, Smith JT, Gayev C, Sawyer A, Pounder RE. Tolerance during 29 days of conventional dosing with cimetidine, nizatidine, famotidine or ranitidine. Aliment Pharmacol Ther 1990; 4 Suppl 1: 29-45
20 Lachman L, Howden CW. Twenty-four-hour intragastric pH: tolerance within 5 days of continuous ranitidine administration. Am J Gastroenterol 2000; 95: 57-61
21 Komazawa Y, Adachi K, Mihara T, Ono M, Kawamura A, Fujishiro H, Kinoshita Y. Tolerance to famotidine and ranitidine treatment after 14 days of administration in healthy subjects without Helicobacter pylori infection. J Gastroenterol Hepatol 2003; 18: 678-682
22 Welage LS. Overview of pharmacologic agents for acid suppression in critically ill patients. Am J Health Syst Pharm 2005; 62: S4-S10
23 Richardson P, Hawkey CJ, Stack WA. Proton pump inhibitors. Pharmacology and rationale for use in gastrointestinal disorders. Drugs 1998; 56: 307-335
24 Sanders SW. Pathogenesis and treatment of acid peptic disorders: comparison of proton pump inhibitors with other antiulcer agents. Clin Ther 1996; 18: 2-34; discussion 1
25 Langtry HD, Markham A. Rabeprazole: a review of its use in acid-related gastrointestinal disorders. Drugs 1999; 58: 725-742
Adachi K, Komazawa Y, Mihara T, Azumi T, Fujisawa T, Katsube T, Furuta K, Kinoshita Y. Comparative study of the speed of acid-suppressing effects of oral administration of cimetidine and famotidine. *J Gastroenterol Hepatol* 2005; 20: 1012-1015

Abe Y, Inamori M, Togawa J, Kikuchi T, Muramatsu K, Chiguchi G, Kawamura H, Kobayashi N, Kirikoshi H, Sakaguchi T, Takamura T, Nakajima A, Ueno N, Sekihara H. The comparative effects of single intravenous doses of omeprazole and famotidine on intragastric pH. *J Gastroenterol* 2004; 39: 21-25

Peghini PL, Katz PO, Bracy NA, Castell DO. Nocturnal recovery of gastric acid secretion with twice-daily dosing of proton pump inhibitors. *Am J Gastroenterol* 1998; 93: 763-767

Katsube T, Adachi K, Kawamura A, Amano K, Uchida Y, Watanabe M, Kinoshita Y. Helicobacter pylori infection influences nocturnal gastric acid breakthrough. *Aliment Pharmacol Ther* 2000; 14: 1049-1056

Katz PO, Anderson C, Khoury R, Castell DO. Gastro-oesophageal reflux associated with nocturnal gastric acid breakthrough on proton pump inhibitors. *Aliment Pharmacol Ther* 1998; 12: 1231-1234

S- Editor Zhu LH  L- Editor Kerr C  E- Editor Lu W